Spots Global Cancer Trial Database for Radium-223 in Combination With Enzalutamide
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Radium-223 in Combination With Enzalutamide
Official Title: A Phase II Study of Radium-223 in Combination With Enzalutamide in Progressive Metastatic Castrate-Resistant Prostate Cancer
Study ID: NCT02225704
Conditions
Interventions
Study Description
Brief Summary: This study aims to determine the safety and tolerability of Radium-223 when administered in combination with enzalutamide in progressive metastatic castrate-resistant prostate cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Cork University Hospital, Cork, , Ireland
Mater Misericordiae University Hospital, Dublin 7, , Ireland
Mater Private Hospital, Dublin 7, , Ireland
SLRON, St James's Hospital, Dublin, , Ireland
St Vincents University Hospital / AMNCH, Dublin, , Ireland
Tallaght Hospital, Dublin, , Ireland
Galway University Hospital, Galway, , Ireland
Contact Details
Name: Ray McDermott, Prof
Affiliation: St Vincent's University Hospital / AMNCH
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
